Genomic Health, Inc.  

(Public, NASDAQ:GHDX)   Watch this stock  
Find more results for GHDX
27.49
-0.11 (-0.40%)
Jul 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 27.23 - 28.12
52 week 23.90 - 37.24
Open 27.79
Vol / Avg. 159,802.00/162,313.00
Mkt cap 858.85M
P/E     -
Div/yield     -
EPS -0.63
Shares 31.24M
Beta 0.54
Inst. own 96%
Jul 28, 2014
Q2 2014 GENOMIC HEALTH INC Earnings Release (Estimated) Add to calendar
Jun 11, 2014
GENOMIC HEALTH INC at Goldman Sachs Healthcare Conference
Jun 5, 2014
GENOMIC HEALTH INC Annual Shareholder Meeting
Jun 2, 2014
GENOMIC HEALTH INC at Jefferies Global Healthcare Conference
May 6, 2014
Q1 2014 GENOMIC HEALTH INC Earnings Conference Call
May 6, 2014
Q1 2014 GENOMIC HEALTH INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -11.11% -4.88%
Operating margin -10.74% -4.77%
EBITD margin - -2.11%
Return on average assets -17.05% -7.71%
Return on average equity -20.97% -9.40%
Employees 684 -
CDP Score - -

Address

301 Penobscot Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-5569300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.

Officers and directors

Kimberly J. Popovits Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
G. Bradley Cole Chief Financial Officer, Chief Operating Officer, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Steven Shak M.D. Executive Vice President - Research and Development
Age: 63
Bio & Compensation  - Reuters
Julian C. Baker Lead Independent Director
Age: 48
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
Felix J. Baker Ph.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D., M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Samuel D. Colella Independent Director
Age: 74
Bio & Compensation  - Reuters